Prescribing without evidence - pregnancy

British Journal of Clinical Pharmacology

Volumn 74, Issue 4, 2012, Pages 691-697

  Thomas, Simon H L ^a,b   Yates, Laura M ^a,b  

^a NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Pregnancy; Prescribing; Teratogen

Indexed keywords

ATENOLOL; CAFFEINE; CARBAMAZEPINE; CITALOPRAM; DIETHYLSTILBESTROL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ISONIAZID; LAMOTRIGINE; LITHIUM; METFORMIN; METHADONE; METOPROLOL; MORPHINE; MORPHINE GLUCURONIDE; NICOTINE; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PHENYTOIN; PROGUANIL; PROTEINASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; THALIDOMIDE; THEOPHYLLINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE; WARFARIN;

ARTICLE; CARCINOGENESIS; CLINICAL TRIAL (TOPIC); CONGENITAL MALFORMATION; DRUG ABSORPTION; DRUG EXCRETION; DRUG SURVEILLANCE PROGRAM; FEMALE GENITAL TRACT MALFORMATION; FETUS MALFORMATION; GLOMERULUS FILTRATION RATE; HUMAN; LICENCE; LIPOPHILICITY; LOW BIRTH WEIGHT; MATERNAL WELFARE; MEDICAL INFORMATION SYSTEM; MEDICAL RECORD; NAUSEA AND VOMITING; NONHUMAN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PLACENTA; PLACENTAL TRANSFER; PLASMA PROTEIN BINDING; PREECLAMPSIA; PREGNANCY; PREMATURITY; PRESCRIPTION; PRIORITY JOURNAL; REGISTER; RISK BENEFIT ANALYSIS; STILLBIRTH; STOMACH EMPTYING; TERATOLOGY;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DATABASES, PHARMACEUTICAL; DRUG PRESCRIPTIONS; DRUG TOXICITY; FEMALE; FETUS; HUMANS; PREGNANCY; PREGNANT WOMEN; REGISTRIES;

EID: 84865858101     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2012.04332.x     Document Type: Article

References (34)

1. Irvine L, Flynn RW, Libby G, Crombie IK, Evans JM. Drugs dispensed in primary care during pregnancy: a record-linkage analysis in Tayside, Scotland. Drug Saf 2010; 33: 593-604.
2. Petersen I, Gilbert RE, Evans SJ, Man SL, Nazareth I. Pregnancy as a major determinant for discontinuation of antidepressants: an analysis of data from The Health Improvement Network. Clin Psychiatry 2011; 72: 979-85.
3. Mitchell AA, Gilboa SM, Werler MM, Kelley KE, Louik C, Hernández-Díaz S and the National Birth Defects Prevention Study. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol 2011; 205: 51.e1-8.
4. Daw JR, Hanley GE, Greyson DL, Morgan SG. Prescription drug use during pregnancy in developed countries: a systematic review. Pharmacoepidemiol Drug Saf 2011; 20: 895-902.
5. NHS Information Centre. NHS Maternity Statistics, England. 2009/10 Available at http://www.ic.nhs.uk/pubs/maternity0910 (last accessed 21 March 2012).
6. Centre for Maternal and Child Enquiries. Saving mothers' lives. Reviewing maternal deaths to make motherhood safer: 2006-2008. Br J Obstet Gynaecol 2011; 118: (Suppl. 1): 1-203.
7. Murphy VE, Namazy JA, Powell H, Schatz M, Chambers C, Attia J, Gibson PG. A meta-analysis of adverse perinatal outcomes in women with asthma. BJOG 2011; 118: 1314-23.
8. Steel JM, Johnstone FD, Hepburn DA, Smith AF. Can prepregnancy care of diabetic women reduce the risk of abnormal babies? BMJ 1990; 301: 1070-4.
9. Kinsley B. Achieving better outcomes in pregnancies complicated by type 1 and type 2 diabetes mellitus. Clin Ther 2007; 29: (Suppl. D): S153-60.
10. Werler MM, Mitchell AA, Shapiro S. The relation of aspirin use during the first trimester of pregnancy to congenital cardiac defects. N Engl J Med 1989; 321: 1639-42.
11. Dieckmann WJ, Davis ME, Rynkiewicz LM, Pottinger RE. Does the administration of diethylstilbestrol during pregnancy have therapeutic value? Am J Obstet Gynecol 1953; 66: 1062-81.
12. Wadelius M, Darj E, Frenne G, Rane A. Induction of CYP2D6 in pregnancy. Clin Pharmacol Ther 1997; 62: 400-7.
13. Tsutsumi K, Kotegawa T, Matsuki S, Tanaka Y, Ishii Y, Kodama Y, Kuranari M, Miyakawa I, Nakano S. The effect of pregnancy on cytochrome P4501A2, xanthine oxidae and N acetyltransferase activities in humans. Clin Pharmacol Ther 2001; 70: 121-5.
14. Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet 2005; 44: 989-1008.
15. Koren G. Pharmacokinetics in pregnancy: clinical significance. J Popul Ther Clin Pharmacol 2011; 18: e523-e527.
16. Anger GJ, Piquette-Miller M. Pharmacokinetic studies in pregnant women. Clin Pharmacol Ther 2008; 83: 184-7.
17. Nakai A, Sekiya I, Oya A, Koshino T, Araki T. Assessment of the hepatic arterial and portal venous blood flows during pregnancy with Doppler ultrasonography. Arch Gynecol Obstet 2002; 266: 25-9.
18. Sit DK, Perel JM, Helsel JC, Wisner KL. Changes in antidepressant metabolism and dosing across pregnancy and early postpartum. J Clin Psychiatry 2008; 6: 652-8.
19. Rubin PC, Butters L, McCabe R, Kelman A. The influence of pregnancy on drug action; concentration-effect modelling with propranolol. Clin Sci 1987; 73: 47-52.
20. Tomi M, Nishimura T, Nakashima E. Mother-to-fetus transfer of antiviral drugs and the importance of transporters at the fetal barrier. J Pharm Sci 2011; 100: 3708-18.
21. Vähäkangas K, Pyllynen P. Drug transporters in the human blood-placental barrier. Br J Pharm 2009; 158: 665-78.
22. Ceccaldi P-F, Gavard L, Mandelbrot L, Rey E, Farinotti R, Jean-Marc Treluyer J-M, Gil S. Functional role of P-glycoprotein and binding protein effect on the placental transfer of lopinavir/ritonavir in the ex vivo human perfusion model. Obstet Gynecol Int 2009; doi:10.1155/2009/726593.
23. Webster WS, Freeman JA. Prescription drugs and pregnancy. Expert Opin Pharmacother 2003; 4: 949-61.
24. Dolk H. EUROCAT: 25 years of European surveillance of congenital anomalies. Arch Dis Child Fetal Neonatal Ed 2005; 90: F355-F358.
25. Meijer WM, Cornel MC, Dolk H, de Walle HE, Armstrong NC, de Jong-van den Berg LT, for the EUROCAT Working Group. The potential of the European network of congenital anomaly registers (EUROCAT) for drug safety surveillance: a descriptive study. Pharmacoepidemiol Drug Saf 2006; 15: 675-82.
26. Garbis H, Elisabeth Elefant B, Diav-Citrin O, Mastroiacovo P, Schaefer C, Vial T, Clementi M, Valti E, McElhatton P, Smorlesi C, Rodriguez EP, Gnansia E, Merlob P, Peiker G, Pexieder T, Schueler L, Ritvanen A, Mathieu-Nolf M. Pregnancy outcome after exposure to ranitidine and other H2-blockers. A collaborative study of the European Network of Teratology Information Services. Reprod Toxicol 2005; 19: 453-8.
27. Kennedy DL, Uhl K, Kweder SL. Pregnancy exposure registries. Drug Saf 2004; 27: 215-28.
28. Tomson T, Battino D, Craig J, Hernandez-Diaz S, Holmes LB, Lindhout D, Morrow J, French J, for the ILAE Commission on Therapeutic Strategies. Pregnancy registries: differences, similarities, and possible harmonization. Epilepsia 2010; 51: 909-15.
29. Morrow J, Russell A, Guthrie E, Parsons L, Robertson I, Waddell R, Irwin B, McGivern RC, Morrison PJ, Craig J. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006; 77: 193-8.
30. Ehrenstein V, Sørensen HT, Bakketeig LV, Pedersen L. Medical databases in studies of drug teratogenicity: methodological issues. Clin Epidemiol 2010; 2: 37-43.
31. Källén BAJ, Olausson PO. Maternal Use of Selective Serotonin Re-Uptake Inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 2007; 79: 301-8.
32. Mølgaard-Nielsen D, Hviid A. Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA 2011; 305: 1996-2002.
33. Charlton RA, Cunnington MC, de Vries CS, Weil JG. Data resources for investigating drug exposure during pregnancy and associated outcomes. The General Practice Research Database (GPRD) as an alternative to pregnancy registries. Drug Saf 2008; 31: 39-51.
34. Suissa S. Immeasurable time bias in observational studies of drug effects on mortality. Am J Epidemiol 2008; 168: 329-35.